Get the Stockscreener App
50.90
1.89%
-0.9542
Crinetics Pharmaceuticals Inc stock is traded at $50.90, with a volume of 50,223.
It is down -1.89% in the last 24 hours and down -11.07% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
See More
Previous Close:
$51.85
Open:
$51.15
24h Volume:
50,223
Relative Volume:
0.07
Market Cap:
$4.71B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-14.93
EPS:
-3.41
Net Cash Flow:
$-203.56M
1W Performance:
-5.73%
1M Performance:
-11.07%
6M Performance:
+13.57%
1Y Performance:
+42.97%
1-Day Range:
$50.67
$51.23
1-Week Range:
$50.67
$54.78
52-Week Range:
$33.67
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
50.78 | 4.71B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
400.89 | 103.35B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
704.13 | 77.35B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
617.11 | 37.04B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.30 | 30.14B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.80 | 26.97B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Stifel Financial Corp Sells 520 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Geode Capital Management LLC - MarketBeat
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook - Investing.com
(CRNX) Trading Advice - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Given Market Outperform Rating at JMP Securities - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Franklin Resources Inc. - MarketBeat
Barclays PLC Acquires 89,358 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer By Investing.com - Investing.com Canada
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Short Interest Update - MarketBeat
Crinetics Pharmaceuticals names new Chief Commercial Officer - Investing.com India
Acromegaly Pipeline Trends 2024: Clinical Trials, Therapeutic - openPR
Isabel Kalofonos Joins Crinetics Pharmaceuticals as Chief Commercial Officer - citybiz
Crinetics appoints Isabel Kalofonos as CCO - TipRanks
JMP Securities Reaffirms Market Outperform Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX) - MarketBeat
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential - Benzinga
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer - The Manila Times
Crinetics Pharma Strengthens Commercial Leadership, Names Veteran Launch Expert as Chief Commercial Officer - StockTitan
Crinetics Pharmaceuticals' SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Australia
Lord Abbett & CO. LLC Decreases Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
State Street Corp Purchases 25,561 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
BNP Paribas Financial Markets Boosts Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Crinetics Pharmaceuticals Awards Stock Options to New Talent in Strategic Expansion Move - StockTitan
Crinetics Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly - Marketscreener.com
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly - The Manila Times
Crinetics' Breakthrough Oral Acromegaly Drug Advances as FDA Accepts NDA for First-in-Class Treatment - StockTitan
Wellington Management Group LLP Sells 160,722 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $70.18 Average Target Price from Analysts - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
73,340 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Bought by Castleark Management LLC - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $13.89 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Certain Stock Option of Crinetics Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 8-DEC-2024. - Marketscreener.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Janus Henderson Group PLC - MarketBeat
Parkman Healthcare Partners LLC Sells 63,752 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Stock Holdings Raised by Charles Schwab Investment Management Inc. - MarketBeat
Cinctive Capital Management LP Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Fmr LLC - MarketBeat
Martingale Asset Management L P Purchases New Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals (FRA:6Z4) EPS (Diluted) : €-3.42 (TTM As of Sep. 2024) - GuruFocus.com
Vestal Point Capital LP Makes New $10.48 Million Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Intech Investment Management LLC Purchases New Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Fisher Asset Management LLC Acquires 37,429 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Congenital Hyperinsulinism Pipeline 2024: Clinical Trials - openPR
Natixis Advisors LLC Purchases 11,870 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Lowers Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Principal Financial Group Inc. Acquires 64,504 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals' SWOT analysis: biotech stock poised for growth with rich pipeline - Investing.com
Jennison Associates LLC Acquires 13,470 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Victory Capital Management Inc. Has $17.55 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Struthers Richard Scott | President & CEO |
Dec 02 '24 |
Sale |
57.57 |
10,000 |
575,700 |
100,000 |
1.65%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):